Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics

Lantern Pharma has a market cap or net worth of $43.46M. The enterprise value is $34.37M.

Lantern Pharma has 10,784,725 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lantern Pharma’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is 516.01%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -20.78B in profits. Earnings per share was -1.93K.

In the last 12 months, operating cash flow was -19.12M and capital expenditures -11.54K, giving a free cash flow of -19.13M billion.

Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lantern Pharma upcoming earnings date is Aug 6, 2025, Before Open (Confirmed).

Lantern Pharma as a current ratio of <0.01, with Debt / Equity ratio of 1.16%

In the past 12 months, Lantern Pharma has paid 0.00 in taxes.

Lantern Pharma EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.52.

Lantern Pharma has $19.72M in cash and marketable securities with $194.93K in debt, giving a net cash position of -$19.53M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy